News & Updates
Showing Multidisciplinary articles
Showing

POETYK trials highlight potential of novel drug for plaque psoriasis
The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Study identifies risk factors for impaired BNT162b2 mRNA antibody response in lupus
Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.

Continuous vital sign monitoring catches COVID-19 deterioration early
A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.






